Rational design, synthesis and testing of novel tricyclic topoisomerase inhibitors for the treatment of bacterial infections part 2.
Journal:
RSC medicinal chemistry
Published Date:
Sep 18, 2020
Abstract
Building on our previously-reported novel tricyclic topoisomerase inhibitors (NTTIs), we disclose the discovery of REDX07965, which has an MIC of 0.5 μg mL against , favourable pharmacokinetic properties, selectivity human topoisomerase II and an acceptable toxicity profile. The results herein validate a rational design approach to address the urgent unmet medical need for novel antibiotics.
Authors
Keywords
No keywords available for this article.